The updated guidance will come into effect from 1 February 2022 for new evaluations

In the last of our series of posts analysing the new access routes developed in the UK, Nasos Kipentzoglou, Analyst at Lightning Health takes an in-depth look at the international routes; the Access Consortium and Project Orbis

In the penultimate of our series of posts analysing the new access routes developed in the UK, Nasos Kipentzoglou, Analyst at Lightning Health takes a deeper dive into the Unfettered Access Procedure for marketing authorisations approved in Northern Ireland 

In the fourth of our series of posts analysing the new access routes developed in the UK, Nasos Kipentzoglou, Analyst at Lightning Health takes a deeper dive into the Decentralised and Mutual Recognition Reliance Procedure 

In the third of our series of posts analysing the new access routes developed in the UK, Nasos Kipentzoglou, Analyst at Lightning Health looks at the European Commission Decision reliance procedure

In the second of our series of posts analysing the new access routes developed in the UK, Nasos Kipentzoglou, Analyst at Lightning Health takes a deeper dive into the rolling review procedure

In the first of a series of articles looking at the mechanisms to obtain marketing authorisation in the UK, Nasos Kipentzoglou, Analyst at Lightning Health takes an in-depth look at the 150-day National Procedure and the possible implications for manufacturers

In the intro of a series of articles, Nasos Kipentzoglou, Analyst at Lightning Health provides a round up of the current mechanisms to obtain marketing authorisation in the UK